Tenaya Therapeutics Q3 net loss narrows
TNYA•Tenaya Therapeutics reported a third-quarter net loss of $18.94 million and an operating loss of $19.57 million. The company expects its cash to fund operations into the fourth quarter of 2027.
1. Quarterly results
Tenaya Therapeutics’ third-quarter operating loss was $19.57 million, compared with an analyst consensus estimate of $22.67 million. Its pretax loss was $18.94 million, versus an estimate of $21.73 million, and operating expenses were $21.27 million.
2. Cash and trials
The company had $66.8 million in cash and cash equivalents as of September 30, 2026, and expects its cash to fund operations into the fourth quarter of 2027. It expects to report longer-term MyPEAK-1 follow-up data and additional interim RIDGE-1 data by year end, and plans to start at least one Phase 2 TN-301 trial in the second half of 2027. The FDA granted RMAT designation to TN-401, supported by positive interim data from RIDGE-1.
